Comparing Modified XELOX Plus Sintilimab With Standard XELOX Plus Sintilimab in First-line Treatment for HER2-negative Gastric/Gastroesophageal Junction Adenocarcinoma

NCT05918094 · clinicaltrials.gov ↗

PHASE3

Phase

RECRUITING

Status

540

Enrollment

OTHER

Sponsor class

Conditions

Gastric Cancer

Interventions

DRUG: Experimental dose: modified XELOX + sintilimab
DRUG: Standard dose: standard XELOX + sintilimab

Sponsor

Sun Yat-sen University